Cargando…

Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score

Detalles Bibliográficos
Autores principales:	D’Agostino, Mattia, Larocca, Alessandra, Offidani, Massimo, Liberati, Anna Marina, Gaidano, Gianluca, Petrucci, Maria Teresa, Derudas, Daniele, Capra, Andrea, Zambello, Renato, Cascavilla, Nicola, de Fabritiis, Paolo, Innao, Vanessa, Bonello, Francesca, Patriarca, Francesca, Benevolo, Giulia, Giuliani, Nicola, Aitoro, Gabriele, Guglielmelli, Tommasina, Di Raimondo, Francesco, Corradini, Paolo, Musto, Pellegrino, Hájek, Roman, Sonneveld, Pieter, Boccadoro, Mario, Bringhen, Sara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8041817/ https://www.ncbi.nlm.nih.gov/pubmed/33846296 http://dx.doi.org/10.1038/s41408-021-00464-w

Ejemplares similares

Place in therapy of innovative drugs in multiple myeloma in 2021 and 2023 according to an expert panel Delphi consensus
por: Mario, Boccadoro, et al.
Publicado: (2021)

First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials
por: Larocca, Alessandra, et al.
Publicado: (2020)

Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial
por: Mina, Roberto, et al.
Publicado: (2021)

Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial
por: Saltarella, Ilaria, et al.
Publicado: (2019)

Diagnostic and Therapeutic Challenges in the Management of Intermediate and Frail Elderly Multiple Myeloma Patients
por: Bonello, Francesca, et al.
Publicado: (2020)

Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs
por: Montefusco, Vittorio, et al.
Publicado: (2020)

Emerging drugs and combinations to treat multiple myeloma
por: Larocca, Alessandra, et al.
Publicado: (2017)

Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies
por: Mina, Roberto, et al.
Publicado: (2020)

P07 BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD) IN REAL-LIFE MULTIPLE MYELOMA PATIENTS INELIGIBLE FOR TRANSPLANT: UPDATED ANALYSIS OF THE RANDOMIZED PHASE IV REAL MM TRIAL
por: Larocca, A., et al.
Publicado: (2023)

Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies
por: Bringhen, Sara, et al.
Publicado: (2019)

The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
por: Bonello, Francesca, et al.
Publicado: (2020)

Experts’ consensus on the definition and management of high risk multiple myeloma
por: Marcon, Chiara, et al.
Publicado: (2023)

Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria
por: Lakshman, Arjun, et al.
Publicado: (2018)

Feasibility of cabazitaxel in octogenarian prostate cancer patients
por: Tralongo, Paolo, et al.
Publicado: (2023)

Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study
por: Mina, Roberto, et al.
Publicado: (2020)

Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria
por: Narita, Kentaro, et al.
Publicado: (2021)

P1680: HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE REAL-LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH FIXED-DURATION BORTEZOMIB-MELPHALAN-PREDNISONE VS. CONTINUOUS LENALIDOMIDE-DEXAMETHASONE
por: D’agostino, Mattia, et al.
Publicado: (2023)

High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions
por: Hagen, Patrick, et al.
Publicado: (2022)

Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma
por: Bonello, Francesca, et al.
Publicado: (2019)

Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project
por: Usmani, Saad Z., et al.
Publicado: (2018)

PB2143: PROGNOSTIC SIGNIFICANCE AND CLINICAL APPLICABILITY OF THE COMORBIDITY INDICES IN PATIENTS WITH MULTIPLE MYELOMA: IMWG AND SARC-F SCORE
por: Vukosavljevic, Nikola, et al.
Publicado: (2023)

Moving Toward Continuous Therapy in Multiple Myeloma
por: Bonello, Francesca, et al.
Publicado: (2019)

Octogenarians Are the New Sexagenarians: Cruciate-Retaining Total Knee Arthroplasty Is Not Inferior to Posterior-Stabilized Arthroplasty in Octogenarian Patients
por: D’Ambrosi, Riccardo, et al.
Publicado: (2022)

Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials
por: Gentile, Massimo, et al.
Publicado: (2020)

Discrepancies between the percentage of plasma cells in bone marrow aspiration and BM biopsy: Impact on the revised IMWG diagnostic criteria of multiple myeloma
por: Lee, N, et al.
Publicado: (2017)

Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma
por: Bonello, Francesca, et al.
Publicado: (2022)

Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study
por: Cascavilla, Nicola, et al.
Publicado: (2015)

Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True
por: D’Agostino, Mattia, et al.
Publicado: (2020)

P932: ON-DEMAND PLERIXAFOR WITH CYCLOPHOSPHAMIDE AND G-CSF FOR HEMATOPOIETIC STEM-CELL MOBILIZATION IN MULTIPLE MYELOMA PATIENTS: FINAL RESULTS OF THE MOZOBL06877 STUDY
por: Mina, R., et al.
Publicado: (2022)

A step ahead toward precision medicine for chronic lymphocytic leukemia
por: Patriarca, Andrea, et al.
Publicado: (2020)

Lenalidomide, Melphalan, and Prednisone Association Is an Effective Salvage Therapy in Relapsed Plasma Cell Leukaemia
por: Guglielmelli, Tommasina, et al.
Publicado: (2009)

Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell’Adulto Multiple Myeloma Working Party study
por: Musto, Pellegrino, et al.
Publicado: (2015)

Neurosurgery in an octogenarian with dementia
por: Andrew, Gemma, et al.
Publicado: (2011)

Radical cystectomy in octogenarians
por: Rawal, Sudhir, et al.
Publicado: (2012)

Cardiac surgery in octogenarians
por: Nussbacher, A, et al.
Publicado: (2005)

REWIND Diabetes for Octogenarians
por: Geberhiwot, Tarekegn
Publicado: (2021)

The Soul of Octogenarian BJORL
por: Neto, Silvio Caldas
Publicado: (2015)

Cardiac surgery in 260 octogenarians: a case series
por: Scandroglio, Anna Mara, et al.
Publicado: (2015)

P36 BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY AGENT AND ONE ANTI-CD38 MONOCLONAL ANTIBODY: A RETRO-PROSPECTIVE ITALIAN OBSERVATIONAL STUDY
por: Offidani, M., et al.
Publicado: (2023)

P1041: LEUKOCYTOSIS SELECTS A SUBGROUP OF LOW-RISK PV PATIENTS IN WHOM PHLEBOTOMY-ALONE MAY BE INSUFFICIENT
por: Carobbio, Alessandra, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7brf299p5s1puu435io7n7c3om